NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety

NEW YORK (July 24, 2014) — Dr. Henry H. Ting, a nationally recognized leader and innovator in health care quality, has been appointed senior vice president and chief quality officer at NewYork-Presbyterian Hospital, effective July 21, 2014. In his new role, he will oversee the hospital's clinical quality and patient safety initiatives.

Dr. Ting has successfully led quality initiatives and interprofessional teams at the local, regional and national levels. Nationally, he led teams for the Door-to-Balloon Alliance, a collaboration of more than 1,000 hospitals to improve treatment and outcomes for patients with severe heart attacks, as well as teams for Hospital-to-Home: Excellence in Transitions of Care, an initiative to reduce 30-day readmission rates for patients hospitalized with congestive heart failure.

Most recently, Dr. Ting was a professor of medicine and served as the associate dean for the Mayo Clinic College of Medicine. He also served as the director for the Mayo Clinic Quality Academy, where he was responsible for quality improvement education, training and coaching for all 60,000 Mayo Clinic staff. His prior positions at the Mayo Clinic include clinical practice chair for the division of cardiovascular diseases and chair of regional cardiovascular practices.

"Dr. Ting is one of the top minds in the country in the field of health care quality," said Dr. Steven J. Corwin, chief executive officer of NewYork-Presbyterian Hospital. "His experience, vision and leadership will help us enhance service across the continuum to deliver the safest, most reliable, and highest-quality care to our patients."

Dr. Ting graduated from Cornell University with a bachelor's degree in chemistry and received his medical degree from Harvard Medical School. He completed his internal medicine residency and fellowship training in cardiovascular diseases and interventional cardiology at Brigham and Women's Hospital in Boston, Massachusetts. Dr. Ting also holds a master's degree in business administration from the University of St. Thomas in Minneapolis, Minnesota. He serves on various national committees, including those for the National Quality Forum, American Board of Internal Medicine, American College of Cardiology, and the American Heart Association. Dr. Ting has published over 120 peer-reviewed papers and serves as the principal investigator for an Agency for Healthcare Research and Quality federal grant.

"NewYork-Presbyterian is one of the top academic medical centers for patient-centered care, research and education," said Dr. Ting. "I am honored and excited to work with our dynamic and creative teams to improve outcomes, safety and service that matter to our patients and communities."

NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital, based in New York City, is one of the nation's largest and most comprehensive hospitals and a leading provider of inpatient, ambulatory, and preventive care in all areas of medicine. With some 2,600 beds and more that 6,500 affiliated physicians and 20,000 employees, NewYork-Presbyterian had more than 2 million visits in 2013, including close to 15,000 infant deliveries and more than 310,000 emergency department visits. NewYork-Presbyterian comprises six campuses: NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian/The Allen Hospital, NewYork-Presbyterian/Westchester Division, and NewYork-Presbyterian/Lower Manhattan Hospital. The hospital is also closely affiliated with NewYork-Presbyterian/Lawrence Hospital in Bronxville. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently named to the U.S. News & World Report Honor Roll of best hospitals in the nation. Affiliated with two world-renowned medical schools, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, NewYork-Presbyterian is committed to excellence in patient care, research, education, and community service. For more information, visit www.nyp.org.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.